What are the latest ESC/ERS guideline recommendations for the management of pulmonary arterial hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ESC/ERS Guidelines for Pulmonary Arterial Hypertension

The most recent ESC/ERS guidelines available in the provided evidence are from 2015, published in 2016 1. However, the research literature references 2022 ESC/ERS guidelines that represent a significant update 2, 3, 4.

Key Updates from 2022 Guidelines (Based on Available Evidence)

Hemodynamic Definitions - Major Change

The 2022 guidelines introduced updated hemodynamic definitions of pulmonary hypertension, including revised thresholds for precapillary vs. postcapillary PH, isolated postcapillary PH (IpcPH), and combined postcapillary and precapillary PH (CpcPH) 2.

Risk Stratification Approach

Multidimensional risk assessment for short-term mortality now guides all treatment decisions in PAH patients without significant comorbidities 4. This represents a shift from the 2015 approach, making risk stratification central to therapeutic strategy.

Treatment Algorithm - 2015 Guidelines (Most Detailed Available)

Initial Treatment Strategy

For Vasoreactive Patients (IPAH/HPAH/DPAH only):

  • Calcium channel blockers (CCB) after positive acute vasoreactivity testing 1

For Non-Vasoreactive, Treatment-Naive Patients:

Low or Intermediate Risk (WHO FC II-III):

  • Initial oral combination therapy with ambrisentan plus tadalafil is superior to monotherapy and receives the highest grade of recommendation 1
  • This combination has proven superiority in delaying clinical failure compared to either agent alone
  • Alternative: Initial monotherapy may be considered, though combination is preferred

High Risk (WHO FC IV):

  • Initial combination therapy including intravenous prostacyclin analogues should be used 1
  • Intravenous epoprostenol should be prioritized as it has demonstrated mortality reduction at 3 months in high-risk PAH patients, even as monotherapy 1

Sequential Treatment for Inadequate Response

Critical Contraindication: The combination of riociguat and PDE-5 inhibitors is contraindicated 1.

Escalation Strategy:

  • If inadequate clinical response to initial therapy: Sequential double or triple combination therapy is recommended 1
  • If inadequate response to double combination: Triple combination therapy should be attempted 1

Lung Transplantation Timing

Consider eligibility for lung transplantation after inadequate response to initial monotherapy or initial combination therapy 1.

Refer for lung transplantation soon after inadequate clinical response is confirmed on maximal combination therapy (Class I recommendation, Level C evidence) 1.

Special Considerations:

  • Bilateral lung transplantation is now the predominant approach worldwide 1
  • PVOD and PCH patients should be listed at diagnosis due to poor prognosis and lack of effective medical treatments 1
  • 5-year survival post-transplant: 52-75%; 10-year survival: 45-66% 1

2022 Guidelines Treatment Recommendations (From Research Evidence)

Updated Initial Therapy Approach

Low to Intermediate Risk Patients:

  • Upfront dual combination therapy (PDE-5 inhibitor + endothelin receptor antagonist) is recommended 4, 5

High or Intermediate-High Risk Patients:

  • Triple therapy including parenteral prostacyclin should be considered 4

Treatment Escalation:

  • If low or intermediate-low risk profile cannot be achieved: Sequential add-on therapy with parenteral prostacyclin or prostacyclin receptor agonist should be considered 4
  • Switching from PDE-5 inhibitor to guanylate cyclase stimulator may be considered 4

Critical Care Management

ICU admission is recommended (Class I, Level C) for PAH patients with:

  • Heart rate >110 beats/min
  • Systolic blood pressure <90 mmHg
  • Low urine output
  • Rising lactate levels 1

Inotropic support is recommended in hypotensive patients (Class I, Level C) 1.

Balloon atrial septostomy may be considered (Class IIb, Level C) after failure of maximal medical therapy as a palliative or bridging procedure 1.

Common Pitfalls

  1. Real-world practice shows significant underutilization of upfront combination therapy: A 2025 US study found 71.3% of newly diagnosed patients received monotherapy despite guidelines recommending combination therapy 5. This likely reflects high rates of cardiopulmonary comorbidities (80-87% of patients) 5.

  2. Risk stratification must be repeated at follow-up every 3-6 months to guide treatment escalation decisions 1.

  3. The 2022 guidelines emphasize patient phenotyping and comorbidities more than previous versions, recognizing that treatment recommendations differ for PAH patients with significant cardiopulmonary comorbidities 2, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.